ANTI-BTN3A ANTIBODIES AND THEIR USE IN TREATING CANCER OR INFECTIOUS DISORDERS

1 . An isolated anti-BTN3A antibody comprising a variable heavy chain polypeptide VH of SEQ ID NO:1 and a variable light chain polypeptide VL of SEQ ID NO:2.

2 . The isolated anti-BTN3A antibody of claim 1 , wherein the antibody binds to human BTN3A polypeptide with a K D of 10 nM or less as measured by surface plasmon resonance.

3 . The isolated anti-BTN3A antibody of claim 1 , wherein the antibody binds to human BTN3A polypeptide with a K D of 5 nM or less as measured by surface plasmon resonance.

4 . The isolated anti-BTN3A antibody of claim 1 , wherein the antibody induces activation of VγVδ2-T cells in co-culture with BTN3 expressing cells, with an EC 50 below 5 μg/m las measured in a degranulation assay.

5 . The isolated anti-BTN3A antibody of claim 1 , wherein the antibody induces activation of VγVδ2-T cells in co-culture with BTN3 expressing cells, with an EC 50 below 1 μg/ml as measured in a degranulation assay.

6 . The isolated anti-BTN3A antibody of claim 1 , wherein the antibody comprises a silenced mutant IgG1 constant region.

7 . The isolated anti-BTN3A antibody of claim 1 , wherein the antibody comprises a IgG1 mutant Fc region with the following three amino acid substitutions: L247F, L248E, and P350S.

8 . The isolated anti-BTN3A antibody of claim 1 , wherein the antibody comprises a heavy chain of SEQ ID NO:4 and a light chain of SEQ ID NO:6.

9 . A pharmaceutical composition comprising an anti-BTN3A antibody of claim 1 , in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.

10 . A lyophilisate formulation, a pre-filled syringe or a vial comprising an anti-BTN3A antibody according to claim 1 .

11 . An expression vector for the recombinant production of an anti-BTN3A antibody of claim 1 in a host cell, comprising at least one nucleic acid encoding the heavy variable chain of SEQ ID NO:1 and a nucleic acid encoding the light variable chain of SEQ ID N:2 of said anti-BTN3A antibody.

12 . The expression vector of claim 11 , comprising a nucleic acid of SEQ ID NO:9 and a nucleic acid of SEQ ID NO:10 encoding respectively the heavy and light chains of said anti-BTN3A antibody.

13 . A mammalian host cell comprising an expression vector according to claim 11 .

14 . A process for the manufacturing of an anti-BTN3A antibody, comprising: (i) culturing the host cell of claim 13 for expression of said antibody by the host cell; optionally (ii) purifying said antibody; and (iii) recovering the antibody.